In our research group, we leverage cutting-edge and innovative methods to identify key cellular mechanisms and molecular markers in atopic dermatitis (AD), aiming to discover new therapeutic targets and biomarkers for disease severity. This work is pivotal for advancing personalized treatment approaches. Our research encompasses both adult and pediatric AD cohorts, with a focus on exploring the complex interplay and regulation between innate and adaptive immune cells. This includes key mechanisms such as trained immunity and immunoregulatory pathways, which play a critical role in disease progression. To date, we have investigated a variety of immunoregulatory molecules in the blood (PBMCs and serum) of AD patients and healthy controls through proteomic analysis. These molecules are crucial in modulating inflammation and present potential targets for improving disease outcomes. Currently, we are conducting scRNA-seq and CyTOF experiments to explore the contributions of different immune cell subgroups to AD pathogenesis. In ongoing and future studies, we employ imaging mass cytometry (IMC) and spatial transcriptomics (10x Genomics) to examine immune cell activity and the expression of immunoregulatory markers in affected skin. These approaches offer a comprehensive view of both systemic and local immune activation in AD, enhancing our understanding of disease progression and therapeutic interventions. For preclinical validation of novel therapeutic targets, we utilize established AD models and assess relevant disease parameters. Moreover, recognizing the essential role of the skin microbiome in immune responses, we also investigate its composition and function in AD patients.